Global Lomitapide Pregnancy Exposure Registry

Study Identifier:
AEGR-733-027
ClinicalTrials.gov Identifier:
NCT02399839
EudraCT Identifier:
N/A
EU CT ID:
N/A
Study Contact Information:
N/A
Terminated/Withdrawn

Study Details

Medical Condition
  • Pregnancy
Study Drug
  • Drug: lomitapide
Date
Oct 2014 - Dec 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female
Age: N/A
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
  • Pregnant females exposed to lomitapide at any time within 30 days prior to first day of the LMP or during pregnancy.
Exclusion Criteria
  • Patients who are unable or unwilling to provide written informed consent or assent are not eligible to participate in the PER.
Healthy Volunteers
No

Protocol Summary

To evaluate the outcomes of pregnancy in women treated with lomitapide.

Study Locations

Location
Status
Location
Klinikum der Universität München
München, Bavaria, Germany, 80336
Status
N/A